Protagonist Therapeutics, Inc.

{
  "main_header": {
    "sid": 1237536,
    "name": "Protagonist Therapeutics, Inc.",
    "stock_name": "Protagonist Therapeutics, Inc.",
    "full_name": "Protagonist Therapeutics, Inc.",
    "name_url": "stocks-analysis/protagonist-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "83.10",
    "chg": -1.69,
    "chgp": "-1.99%",
    "dir": -1,
    "prev_price": "84.79",
    "mcapval": "5,244.44",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US74366E1029",
    "curr_date": "Jan 23",
    "curr_time": "",
    "bse_nse_vol": "1.14 M",
    "exc_status": "Active",
    "traded_date": "Jan 23, 2026",
    "traded_date_str": "2026 01 23",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/protagonist-therapeutics-inc-1237536-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protagonist-therapeutics-sees-valuation-grade-shift-from-expensive-to-very-expensive-3686311",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtagonistTher_valuationdot_3686311.png",
        "date": "2025-11-10 16:10:50",
        "description": "Protagonist Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 60 and other elevated financial metrics. The company has outperformed the S&P 500 significantly, with a 67.07% return over the past year and an impressive 106.06% year-to-date, highlighting its strong market position."
      }
    ],
    "total": 25,
    "sid": "1237536",
    "stock_news_url": "https://www.marketsmojo.com/news/protagonist-therapeutics-inc-1237536"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Protagonist Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance

2025-11-10 16:10:50

Protagonist Therapeutics, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 60 and other elevated financial metrics. The company has outperformed the S&P 500 significantly, with a 67.07% return over the past year and an impressive 106.06% year-to-date, highlighting its strong market position.

Read full news article

View All News